In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).

People with lupus have a higher risk of hearing loss due to inflammation that can damage the inner ear and auditory pathways. Hearing loss is a lesser-known complication of lupus, but it can ...

Systemic lupus erythematosus commonly presents as a rash. The rashes are caused by inflammation from the immune system fighting the body. Systemic lupus erythematosus, more commonly known as lupus ...

Jan. 21, 2025 — Researchers identified a key protein as a potential therapeutic target for stopping the body's immune system from mistakenly attacking itself, offering new hope for treating ...

Hypoglycemia (low blood sugar) is not a formal symptom of lupus, but it may develop from related factors like medication use, other autoimmune processes in the body, and hormonal changes.

Although the age of onset of lupus is typically between 15 and 44 years old, up to 25% of people diagnosed with systemic lupus erythematosus (SLE) have late-onset lupus. Lupus is most commonly ...

Lupus panniculitis is a rare type of lupus. It causes painful lumps under the skin that may lead to scarring. Treatments can help reduce the risk of complications. Lupus is a chronic autoimmune ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

January is Mental Wellness Month! We asked Heather Rose Artushin, a licensed clinical social worker, to share information and insights into understanding and protecting your mental health when you ...

HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual’s risk for flares and retinal toxicity. GC are used as ‘bridging therapy’ ...

Chilblain lupus erythematosus (CHLE) is a rare type of cutaneous lupus erythematosus (CLE). Symptoms, such as lesions and swelling, can develop after exposure to cold temperatures. CHLE may have a ...

Anifrolumab targets the type I interferon signalling pathway, which plays a role in the pathogenesis of lupus nephritis (LN). This phase II ... changes to the cut-off values for the renal function and ...